Certara/ US15687V1098 /
2024-04-24 9:59:36 PM | Chg. -0.27 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
16.43USD | -1.59% | 8,897 Turnover: 146,632.31 |
-Bid Size: - | -Ask Size: - | 16.72 | 16.34 |
GlobeNewswire
04-16
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
GlobeNewswire
04-09
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA ...
GlobeNewswire
02-01
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Par...
GlobeNewswire
2023-12-13
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabili...
GlobeNewswire
2023-11-21
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic dru...
GlobeNewswire
2023-10-27
Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosi...
GlobeNewswire
2023-10-11
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the...
GlobeNewswire
2023-09-19
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and So...
GlobeNewswire
2022-02-15
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year
GlobeNewswire
2022-02-08
Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022
GlobeNewswire
2021-12-21
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regula...
GlobeNewswire
2021-12-02
Certara Announces Release of Simcyp™ Simulator Version 21, Expanding Capabilities to Align with Rece...
GlobeNewswire
2021-11-15
EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel